$6.69 Billion is the total value of Avoro Capital Advisors LLC's 36 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | Buy | HORIZON THERAPEUTICS PLC | $796,600,000 | +151.1% | 7,000,000 | +36.6% | 11.90% | +103.2% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $549,418,750 | -20.6% | 10,625,000 | +4.9% | 8.21% | -35.7% |
| MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $481,815,000 | +383.0% | 1,660,000 | +8.1% | 7.20% | +290.7% |
| ASND | Buy | ASCENDIS PHARMAsponsored adr | $378,603,000 | +28.6% | 3,100,000 | +8.8% | 5.66% | +4.1% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $251,722,197 | -35.1% | 5,555,555 | +0.1% | 3.76% | -47.5% |
| SGEN | Buy | SEAGEN INC | $242,241,350 | -5.1% | 1,885,000 | +1.1% | 3.62% | -23.2% |
| ISEE | Buy | IVERIC BIO INC | $144,517,500 | +36.5% | 6,750,000 | +14.4% | 2.16% | +10.5% |
| KRYS | Buy | KRYSTAL BIOTECH INC | $111,700,200 | +25.7% | 1,410,000 | +10.6% | 1.67% | +1.6% |
| KYMR | Buy | KYMERA THERAPEUTICS INC | $96,096,000 | +103.5% | 3,850,000 | +77.5% | 1.44% | +64.7% |
| Buy | DICE THERAPEUTICS INC | $78,797,316 | +261.4% | 2,525,555 | +134.9% | 1.18% | +192.3% | |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $67,442,500 | +26.3% | 2,650,000 | +19.3% | 1.01% | +2.1% |
| Buy | NUVALENT INC | $46,324,428 | +127.1% | 1,555,555 | +48.2% | 0.69% | +83.6% | |
| RNA | Buy | AVIDITY BIOSCIENCES INC | $45,489,500 | +92.1% | 2,050,000 | +41.4% | 0.68% | +55.6% |
| GLUE | Buy | MONTE ROSA THERAPEUTICS INC | $32,913,250 | +19.8% | 4,325,000 | +28.6% | 0.49% | -3.1% |
| DSGN | Buy | DESIGN THERAPEUTICS INC | $23,312,998 | -37.3% | 2,272,222 | +2.3% | 0.35% | -49.3% |
| Buy | TANGO THERAPEUTICS INC | $11,890,000 | +111.9% | 1,640,000 | +5.8% | 0.18% | +71.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.